Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery
Obesity · 2026-08 · 34 (8) · 1583-1591
DOI: 10.1002/oby.70246 ↗At a glance
Vergleichsstudie in Obesity, published online on 2026-06-25. Written by Avery Brown and 14 co-authors. Institution: Division of Bariatric and General Surgery, NYC Health+Hospitals/Bellevue, New York, New York, USA. Major MEDLINE topics: Tirzepatide, Glucagon-Like Peptides, Bariatric Surgery, Obesity, Morbid. Cited 4 times so far (Crossref); 29 references. The full text is freely available in PubMed Central. Funded by: NCATS NIH HHS, NIDDK NIH HHS, NIH HHS.
Abstract (original language)
Objective
Directly compare the real‐world effectiveness of semaglutide and tirzepatide to bariatric operations: sleeve gastrectomy and gastric bypass.
Methods
This study included adults with BMI ≥ 35 who received injectable semaglutide or tirzepatide (GLP‐1RAs) or sleeve gastrectomy or gastric bypass (bariatric surgery) at two urban health systems from 2018 to 2024. Total weight loss (TWL) was compared up to 3 years post treatment with inverse probability weighting and mixed linear models. Intention‐to‐treat (any GLP‐1RA) and per‐protocol (1 year of continuous GLP‐1RA orders) analyses were performed.
Results
Of 44,025 patients studied, bariatric surgery was associated with greater weight loss at 1, 2, and 3 years post treatment: semaglutide ( n = 25,804) TWL (95% CI): 5.4% (5.3%–5.6%), 6.5% (6.4%–6.7%), and 7.4% (7.3%–7.6%); tirzepatide ( n = 7308): 9.1% (8.9%–9.4%) and 10.8% (10.2%–11.3%); sleeve gastrectomy ( n = 8728): 24.4% (24.3%–24.6%), 22.4% (22.3%–22.5%), and 22.0% (21.8%–22.1%); gastric bypass ( n = 2185): 29.8% (29.7%–29.9%), 28.1% (28.0%–28.2%), and 28.4% (28.3%–28.5%). With 1 year of continuous GLP‐1RA, findings were: semaglutide TWL: 7.2% (7.0%–7.4%), 8.0% (7.8%–8.2%), and 8.8% (8.6%–9.0%); tirzepatide TWL: 11.7% (11.4%–11.9%) and 11.9% (11.5%–12.3%).
Conclusions
In this retrospective two‐center study, bariatric surgery was associated with greater weight loss than GLP‐1RAs among patients eligible for both options.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Division of Bariatric and General Surgery, NYC Health+Hospitals/Bellevue, New York, New York, USA.
- Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA.
- Center for Surgical and Transplant Applied Research, NYU Langone Health, New York, New York, USA.
- Department of Population Health, NYU Grossman School of Medicine, New York, New York, USA.
- Department of Surgery, NYU Langone Hospital-Brooklyn, Brooklyn, New York, USA.
ORCID profiles: Akio Kozato, Karan R Chhabra
Funding
- NCATS NIH HHS
- NIDDK NIH HHS
- NIH HHS
- National Institutes of Health
Cite
APA
Brown, A., Patel, S. S., Kozato, A., Orandi, B. J., Massie, A., Vu, A. H., Somoza, E., Mei, T., Desai, S., Zhang, D. S., Segev, D., Welcome, A. U., Ren-Fielding, C., Parikh, M., & Chhabra, K. R. (2026). Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity, 34(8), 1583-1591. https://doi.org/10.1002/oby.70246
Vancouver
Brown A, Patel SS, Kozato A, Orandi BJ, Massie A, Vu AH, et al. Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery. Obesity. 2026;34(8):1583-1591. doi:10.1002/oby.70246
BibTeX
@article{Brown2026,
author = {Brown, Avery and Patel, Suhani S and Kozato, Akio and Orandi, Babak J and Massie, Allan and Vu, Alexander Hien and Somoza, Eduardo and Mei, Tony and Desai, Sunita and Zhang, Donglan S and Segev, Dorry and Welcome, Akuezunkpa Ude and Ren-Fielding, Christine and Parikh, Manish and Chhabra, Karan R},
title = {Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery},
journal = {Obesity},
year = {2026},
volume = {34},
number = {8},
pages = {1583--1591},
doi = {10.1002/oby.70246}
}
EUVIMED